DIVISLAB - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 3.2
| Stock Code | DIVISLAB | Market Cap | 1,61,098 Cr. | Current Price | 6,068 ₹ | High / Low | 7,078 ₹ |
| Stock P/E | 64.1 | Book Value | 578 ₹ | Dividend Yield | 0.50 % | ROCE | 20.6 % |
| ROE | 15.6 % | Face Value | 2.00 ₹ | DMA 50 | 6,284 ₹ | DMA 200 | 6,228 ₹ |
| Chg in FII Hold | 0.69 % | Chg in DII Hold | -0.50 % | PAT Qtr | 696 Cr. | PAT Prev Qtr | 557 Cr. |
| RSI | 43.1 | MACD | -93.3 | Volume | 3,29,545 | Avg Vol 1Wk | 3,52,649 |
| Low price | 4,942 ₹ | High price | 7,078 ₹ | PEG Ratio | -6.97 | Debt to equity | 0.01 |
| 52w Index | 52.8 % | Qtr Profit Var | 34.4 % | EPS | 94.7 ₹ | Industry PE | 29.1 |
📊 Analysis: DIVISLAB is trading at 6,068 ₹, below both its 50 DMA (6,284 ₹) and 200 DMA (6,228 ₹), showing weak technical strength. RSI at 43.1 indicates bearish-to-neutral momentum, while MACD (-93.3) suggests strong bearish undertone. Current volume (3.29L) is slightly below the 1-week average (3.52L), pointing to moderate intraday participation. The setup favors cautious trades with limited upside potential.
💰 Optimal Buy Price: 6,050–6,080 ₹ (near support zone)
📈 Profit-Taking Levels: 6,120–6,180 ₹ (short-term resistance)
⚠️ Stop-Loss: 6,020 ₹ (below support)
⏳ If Already Holding: Exit intraday if price fails to sustain above 6,050 ₹ or if RSI dips below 42 with weakening momentum. Book profits near 6,120–6,180 ₹ if momentum slows. Watch MACD widening negatively as a clear exit signal.
Positive
- Strong ROCE (20.6%) and ROE (15.6%) indicate efficient capital use.
- Debt-free balance sheet (Debt-to-equity 0.01).
- Quarterly PAT growth (696 Cr. vs 557 Cr.), up 34.4%.
- EPS of 94.7 ₹ supports valuation strength.
- FII holdings increased (+0.69%), reflecting foreign investor confidence.
Limitation
- Trading below both 50 DMA and 200 DMA, showing weak technicals.
- High P/E (64.1) compared to industry average (29.1), suggesting overvaluation.
- MACD strongly negative, indicating weak short-term momentum.
- PEG ratio (-6.97) signals poor valuation relative to growth.
- DII holdings decreased (-0.50%), showing reduced domestic support.
Company Negative News
- No major external negative news reported, but valuation concerns and weak momentum indicators are notable.
Company Positive News
- Quarterly PAT growth of 34.4% shows strong earnings momentum.
- FII holdings increased, reflecting confidence from foreign institutions.
Industry
- Industry P/E at 29.1 is much lower than DIVISLAB’s P/E (64.1), highlighting relative overvaluation.
- Pharmaceutical sector remains resilient with global demand, though valuations are stretched.
Conclusion
🔎 DIVISLAB offers limited intraday potential with support near 6,050 ₹ and resistance around 6,120–6,180 ₹. Momentum indicators suggest caution, as MACD is strongly negative and RSI is weak. Best strategy: Buy near support, exit near resistance, and protect downside with a strict stop-loss at 6,020 ₹.